Literature DB >> 21111000

A novel imaging-compatible sciatic nerve schwannoma model.

Okay Saydam1, Gokhan Baris Ozdener, Ozlem Senol, Arda Mizrak, Shilpa Prabhakar, Anat O Stemmer-Rachamimov, Xandra O Breakefield, Gary J Brenner.   

Abstract

Benign schwannomas are common tumors of the cranial and peripheral nerves, causing pain and loss of function. The development of effective therapy for these tumors has been hampered by the lack of relevant experimental in vivo models for convenient testing. Here, we describe a novel schwannoma model in which an immortalized human schwannoma cell line, HEI-193, established from an neurofibromatosis type 2 patient, has been stably transduced with fluorescent protein and luciferase reporters and implanted within the sciatic nerve of nude mice. These cells reliably formed a tumor within several weeks which had pathologic characteristics of schwannoma tumors. This model system will be useful for investigation of schwannoma biology and for preclinical assessment of therapeutic agents.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21111000      PMCID: PMC3032262          DOI: 10.1016/j.jneumeth.2010.10.021

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  11 in total

1.  Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein.

Authors:  M Giovannini; E Robanus-Maandag; M Niwa-Kawakita; M van der Valk; J M Woodruff; L Goutebroze; P Mérel; A Berns; G Thomas
Journal:  Genes Dev       Date:  1999-04-15       Impact factor: 11.361

2.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

3.  Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.

Authors:  Shanta M Messerli; Shilpa Prabhakar; Yi Tang; Umar Mahmood; Marco Giovannini; Ralph Weissleder; Rodrick Bronson; Robert Martuza; Samuel Rabkin; Xandra O Breakefield
Journal:  Hum Gene Ther       Date:  2006-01       Impact factor: 5.695

4.  Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2.

Authors:  Gene Hung; Xiankui Li; Rodolfo Faudoa; Zhu Xeu; Lan Kluwe; Johng S Rhim; William Slattery; David Lim
Journal:  Int J Oncol       Date:  2002-03       Impact factor: 5.650

5.  Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.

Authors:  Georgette N Jones; Chhavy Tep; William H Towns; Georgeta Mihai; Ian D Tonks; Graham F Kay; Petra M Schmalbrock; Anat O Stemmer-Rachamimov; Sung Ok Yoon; Lawrence S Kirschner
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

6.  Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.

Authors:  Okay Saydam; Yiping Shen; Thomas Würdinger; Ozlem Senol; Elvan Boke; Marianne F James; Bakhos A Tannous; Anat O Stemmer-Rachamimov; Ming Yi; Robert M Stephens; Cornel Fraefel; James F Gusella; Anna M Krichevsky; Xandra O Breakefield
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

7.  Peripheral noxious stimulation induces phosphorylation of the NMDA receptor NR1 subunit at the PKC-dependent site, serine-896, in spinal cord dorsal horn neurons.

Authors:  Gary J Brenner; Ru-Rong Ji; Sebastian Shaffer; Clifford J Woolf
Journal:  Eur J Neurosci       Date:  2004-07       Impact factor: 3.386

8.  Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis.

Authors:  C Boyd; M J Smith; L Kluwe; A Balogh; M Maccollin; S R Plotkin
Journal:  Clin Genet       Date:  2008-07-21       Impact factor: 4.438

Review 9.  Neurofibromatosis 2 (bilateral acoustic neurofibromatosis).

Authors:  R L Martuza; R Eldridge
Journal:  N Engl J Med       Date:  1988-03-17       Impact factor: 91.245

10.  A highly sensitive assay for monitoring the secretory pathway and ER stress.

Authors:  Christian E Badr; Jeffrey W Hewett; Xandra O Breakefield; Bakhos A Tannous
Journal:  PLoS One       Date:  2007-06-27       Impact factor: 3.240

View more
  13 in total

Review 1.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

2.  Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo.

Authors:  Sherif G Ahmed; Ahmed Abdelnabi; Casey A Maguire; Mohamed Doha; Jessica E Sagers; Rebecca M Lewis; Alona Muzikansky; Marco Giovannini; Anat Stemmer-Rachamimov; Konstantina M Stankovic; Giulia Fulci; Gary J Brenner
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

Review 3.  Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma.

Authors:  Justin Hall; Shilpa Prabhakar; Leonora Balaj; Charles P Lai; Richard A Cerione; Xandra O Breakefield
Journal:  Cell Mol Neurobiol       Date:  2016-03-26       Impact factor: 5.046

4.  Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1.

Authors:  Shilpa Prabhakar; Mehran Taherian; Davide Gianni; Thomas J Conlon; Giulia Fulci; Jillian Brockmann; Anat Stemmer-Rachamimov; Miguel Sena-Esteves; Xandra O Breakefield; Gary J Brenner
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

5.  miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways.

Authors:  Okay Saydam; Ozlem Senol; Thomas Würdinger; Arda Mizrak; Gokhan Baris Ozdener; Anat O Stemmer-Rachamimov; Ming Yi; Robert M Stephens; Anna M Krichevsky; Nurten Saydam; Gary J Brenner; Xandra O Breakefield
Journal:  Cancer Res       Date:  2010-12-13       Impact factor: 12.701

6.  Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.

Authors:  Shilpa Prabhakar; Roberta L Beauchamp; Pike See Cheah; Akiko Yoshinaga; Edwina Abou Haidar; Sevda Lule; Gayathri Mani; Katia Maalouf; Anat Stemmer-Rachamimov; David H Jung; D Bradley Welling; Marco Giovannini; Scott R Plotkin; Casey A Maguire; Vijaya Ramesh; Xandra O Breakefield
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-22       Impact factor: 5.849

7.  Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter.

Authors:  S Prabhakar; G J Brenner; B Sung; S M Messerli; J Mao; M Sena-Esteves; A Stemmer-Rachamimov; B Tannous; X O Breakefield
Journal:  Cancer Gene Ther       Date:  2009-10-16       Impact factor: 5.987

8.  FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.

Authors:  Silvia Licciulli; Jasna Maksimoska; Chun Zhou; Scott Troutman; Smitha Kota; Qin Liu; Sergio Duron; David Campbell; Jonathan Chernoff; Jeffrey Field; Ronen Marmorstein; Joseph L Kissil
Journal:  J Biol Chem       Date:  2013-08-19       Impact factor: 5.157

9.  Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas.

Authors:  Phanidhar Kukutla; Sherif G Ahmed; Daniel M DuBreuil; Ahmed Abdelnabi; Murat Cetinbas; Giulia Fulci; Berent Aldikacti; Anat Stemmer-Rachamimov; Scott R Plotkin; Brian Wainger; Ruslan I Sadreyev; Gary J Brenner
Journal:  Ann Clin Transl Neurol       Date:  2021-05-30       Impact factor: 4.511

10.  Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth.

Authors:  Arda Mizrak; Mehmet Fatih Bolukbasi; Gokhan Baris Ozdener; Gary J Brenner; Sibylle Madlener; Erdogan Pekcan Erkan; Thomas Ströbel; Xandra O Breakefield; Okay Saydam
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.